In this article

What are amylase and lipase?

Amylase and lipase are digestive enzymes produced by the pancreas.

  • Amylase helps break down carbohydrates
  • Lipase helps break down fats

In clinical settings, these enzymes are often measured when acute pancreatitis is suspected, as they can rise during active pancreatic inflammation.

However, their role is primarily diagnostic during an acute event, rather than predictive of future risk.

Why we do not rely on amylase and lipase for GLP-1 pancreatitis risk screening?

GLP-1 receptor agonists (such as semaglutide and similar medications) have been associated with pancreatitis. Because of this, monitoring pancreatic safety is important, but enzyme testing alone is not an effective screening tool for risk prediction.

There are several reasons for this:

  • They rise acutely after inflammation beginsAmylase and lipase typically increase once pancreatic injury is already underway, not before symptoms develop.
  • They are not specific for GLP-1–related riskElevated levels may occur due to gallstones, gastrointestinal conditions, kidney dysfunction, or other non-pancreatic causes.
  • They may remain normal in some clinically significant casesParticularly in early, mild, or atypical presentations, enzyme levels can be misleadingly normal.

Because of this, relying solely on these biomarkers may miss early warning signs or overestimate risk in unrelated conditions.

How pancreatitis risk is assessed in GLP-1 users

Instead of routine enzyme testing, pancreatitis risk is better evaluated using a symptom- and risk-factor–based approach, especially in individuals using GLP-1 therapy.

This is why our program includes:

  • Structured symptom questionnaires
  • Medical and medication history review
  • Metabolic risk profiling
  • Identification of known pancreatitis risk factors

Key risk factors may include:

  • History of gallstones
  • High triglycerides
  • Excess alcohol intake
  • Prior episodes of unexplained abdominal pain
  • Rapid metabolic changes or weight loss
  • Concurrent medications affecting pancreatic or biliary function

This approach focuses on early identification of clinical risk patterns rather than late biochemical changes.

What symptoms are important to monitor?

Important symptoms to monitor include:

  • Persistent upper abdominal pain (especially central)
  • Pain that radiates to the back
  • Nausea or vomiting that does not resolve
  • Pain that worsens after eating
  • Abdominal tenderness or bloating
  • Sudden loss of appetite with gastrointestinal discomfort

If these symptoms are severe, persistent, or worsening, medical evaluation is necessary.

How to reduce pancreatitis risk while on GLP-1 therapy

For individuals using GLP-1 medications, risk reduction focuses on supporting overall pancreatic and metabolic health:

  • Avoid or limit alcohol intake
  • Maintain healthy triglyceride levels through diet, exercise and regular monitoring
  • Follow appropriate dose escalation protocols for GLP-1 therapy
  • Manage gallstone risk where relevant (especially during rapid weight loss)
  • Maintain hydration and balanced nutrition during appetite suppression
  • Report persistent gastrointestinal symptoms early rather than waiting for lab changes

These strategies help reduce the likelihood of pancreatic stress during treatment.

Where can I learn more?

If you want to better understand pancreatitis risk in the context of GLP-1 medications, it is useful to explore our referenced literature: